Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    11483335 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: < 15% risk of + LN;   Radiation: > 15% risk of + LN
2 Recruiting Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE;   Radiation: Proton (prostate bed) to 70.2 CGE;   Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE;   Radiation: Proton to 66.6 CGE
3 Active, not recruiting Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
Condition: Prostate Adenocarcinoma
Interventions: Drug: Goserelina 4 months and Bicalutamida;   Drug: Goserelina

Indicates status has not been verified in more than two years